DULOXETINE

Generic: DULOXETINE

Actavis PharmaManufacturer
ORALRoute
DULOXETINE HYDROCHLORIDEActive Substance
2013-12-17Original Approval

DULOXETINE is FDA application ANDA090776, sponsored by ACTAVIS ELIZABETH. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class III2017-11-21
Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc.

Failed Dissolution Specification

Class II2025-07-15
Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L.

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

Class II2024-12-06
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutica

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Class III2015-10-21
Duloxetine Delayed-release Capsules, USP, 60 mg, Rx Only, 1000 count bottle, Manufactured by: Laboratorios Dr. Esteve, S

Presence of Foreign Tablets/Capsules: one foreign capsule identified as omeprazole 10 mg was found i

Class II2025-11-24
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Eu

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Class II2025-04-14
Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe,

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim

Class II2025-04-14
Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim

Class II2025-07-25
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutica

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Class II2026-04-29
Duloxetine Delayed-Release Capsules, 30 mg, Rx Only, a) 90 Capsules, NDC 27241-098-09, b) 30 capsules, NDC 27241-098-03,

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm,

Class II2025-11-24
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Eu

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Top Reported Reactions

1
DRUG INEFFECTIVE
5,654 reports
2
NAUSEA
5,344 reports
3
FATIGUE
5,240 reports
4
OFF LABEL USE
4,568 reports
5
HEADACHE
4,048 reports
6
PAIN
4,037 reports
7
DIARRHOEA
3,613 reports
8
DIZZINESS
3,330 reports
9
FALL
3,055 reports
10
VOMITING
2,710 reports